PMID- 18447905
OWN - NLM
STAT- MEDLINE
DCOM- 20080626
LR  - 20211020
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 8
DP  - 2008 Apr 30
TI  - Differential effects of antibiotics in combination with G-CSF on survival and 
      polymorphonuclear granulocyte cell functions in septic rats.
PG  - 55
LID - 10.1186/1471-2334-8-55 [doi]
AB  - BACKGROUND: In addition to their antimicrobial activity, antibiotics modulate 
      cellular host defence. Granulocyte-colony stimulating factor (G-CSF) is also a 
      well known immunomodulator; however little is known about the interactions of 
      G-CSF with antibiotics. We investigated in septic rats the effects of two 
      antibiotic combinations with G-CSF. METHODS: In two clinic modelling randomised 
      trials (CMRTs), male Wistar rats were anesthetized, given antibiotic prophylaxis, 
      had a laparotomy with peritoneal contamination and infection (PCI), and were 
      randomly assigned (n = 18 rats/group) to: 1) PCI only; 2) PCI+antibiotic; and, 3) 
      PCI+antibiotic+G-CSF prophylaxis (20 mug/kg, three times). This sequence was 
      conducted first with 10 mg/kg coamoxiclav, and then with 
      ceftriaxone/metronidazole (Cef/met, 10/3 mg/kg). In additional animals, the blood 
      cell count, migration and superoxide production of PMNs, systemic TNF-alpha and 
      liver cytokine mRNA expression levels were determined. RESULTS: Only the 
      combination coamoxiclav plus G-CSF improved the survival rate (82 vs. 44%, p < 
      0.001). Improved survival with this combination was accompanied by normalised 
      antimicrobial PMN migratory activity and superoxide production, along with 
      normalised systemic TNF-alpha levels and a reduced expression of TNF-alpha and 
      IL-1 in the liver. CONCLUSION: There are substantial differences in the 
      interaction of antibiotics with G-CSF. Therefore, the selection of the antibiotic 
      for combination with G-CSF in sepsis treatment should be guided not only by the 
      bacteria to be eliminated, but also by the effects on antimicrobial functions of 
      PMNs and the cytokine response.
FAU - Bauhofer, Artur
AU  - Bauhofer A
AD  - Institute of Theoretical Surgery, Philipps-University Marburg, Baldingerstrasse, 
      35033 Marburg, Germany. a-bauhofer@web.de
FAU - Huttel, Markus
AU  - Huttel M
FAU - Lorenz, Wilfried
AU  - Lorenz W
FAU - Sessler, Daniel I
AU  - Sessler DI
FAU - Torossian, Alexander
AU  - Torossian A
LA  - eng
PT  - Journal Article
DEP - 20080430
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-1)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11062-77-4 (Superoxides)
RN  - 140QMO216E (Metronidazole)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination)
RN  - 75J73V1629 (Ceftriaxone)
SB  - IM
MH  - Amoxicillin-Potassium Clavulanate Combination/administration & dosage
MH  - Animals
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - *Antibiotic Prophylaxis
MH  - Ceftriaxone/administration & dosage
MH  - Chemotaxis
MH  - Cytokines/analysis/metabolism
MH  - Drug Administration Schedule
MH  - Drug Evaluation, Preclinical
MH  - Drug Therapy, Combination
MH  - Feces/microbiology
MH  - Granulocyte Colony-Stimulating Factor/*administration & dosage
MH  - Granulocytes/*physiology
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Interleukin-1/metabolism
MH  - Liver/immunology/metabolism
MH  - Male
MH  - Metronidazole/administration & dosage
MH  - Rats
MH  - Rats, Wistar
MH  - Recombinant Proteins
MH  - Sepsis/*immunology/*prevention & control
MH  - Superoxides/analysis/metabolism
MH  - Survival Rate
MH  - Tumor Necrosis Factor-alpha/biosynthesis/blood
PMC - PMC2386131
EDAT- 2008/05/02 09:00
MHDA- 2008/06/27 09:00
PMCR- 2008/04/30
CRDT- 2008/05/02 09:00
PHST- 2007/10/08 00:00 [received]
PHST- 2008/04/30 00:00 [accepted]
PHST- 2008/05/02 09:00 [pubmed]
PHST- 2008/06/27 09:00 [medline]
PHST- 2008/05/02 09:00 [entrez]
PHST- 2008/04/30 00:00 [pmc-release]
AID - 1471-2334-8-55 [pii]
AID - 10.1186/1471-2334-8-55 [doi]
PST - epublish
SO  - BMC Infect Dis. 2008 Apr 30;8:55. doi: 10.1186/1471-2334-8-55.